Actively Recruiting
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
Led by Johns Hopkins University · Updated on 2026-02-17
120
Participants Needed
9
Research Sites
201 weeks
Total Duration
On this page
Sponsors
J
Johns Hopkins University
Lead Sponsor
N
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+/R-) kidney transplants. Participants will be randomized into one of two groups: Arm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks. Arm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.
CONDITIONS
Official Title
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant meets the standard criteria for kidney transplant at the local center
- Participant can understand and provide informed consent
- Participant is 18 years old or older
You will not qualify if you...
- Participant has active Hepatitis C Virus infection (detectable HCV RNA) at screening
- Participant has cirrhosis or advanced liver fibrosis
- Participant's liver enzymes (AST or ALT) are more than 2.5 times the normal limit within 60 days of screening
- Participant has human immunodeficiency virus (HIV) or active hepatitis B infection
- Participant cannot safely stop or replace a medication that conflicts with the study drug
- Participant has medical conditions that increase risk, interfere with study participation, or affect data quality
- Participant is pregnant or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 9 locations
1
University of California San Diego
La Jolla, California, United States, 92037
Actively Recruiting
2
Loma Linda University Health
Loma Linda, California, United States, 92408
Actively Recruiting
3
Johns Hopkins University
Baltimore, Maryland, United States, 21205
Actively Recruiting
4
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
5
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
6
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Actively Recruiting
7
University of Utah Medical Center
Salt Lake City, Utah, United States, 84132
Actively Recruiting
8
Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Actively Recruiting
9
University of Wisconsin, Madison
Madison, Wisconsin, United States, 53792
Terminated
Research Team
C
Christine Durand, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here